Astaxanthin: A Potential Therapeutic Agent in Cardiovascular Disease

被引:220
|
作者
Fassett, Robert G. [1 ,2 ,3 ]
Coombes, Jeff S. [3 ]
机构
[1] Renal Res Royal Brisbane & Womens Hosp, Brisbane, Qld 4029, Australia
[2] Univ Queensland, Sch Med, Brisbane, Qld 4029, Australia
[3] Univ Queensland, Sch Human Movement Studies, Brisbane, Qld 4072, Australia
关键词
antioxidants; xanthophyll carotenoid; inflammation; Haematococcus pluvialis; oxidative stress; CORONARY-HEART-DISEASE; VITAMIN-E CONSUMPTION; BETA-CAROTENE; OXIDATIVE STRESS; ALPHA-TOCOPHEROL; IN-VITRO; LIPID-PEROXIDATION; PLASMA APPEARANCE; GENE-EXPRESSION; RENAL-DISEASE;
D O I
10.3390/md9030447
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Astaxanthin is a xanthophyll carotenoid present in microalgae, fungi, complex plants, seafood, flamingos and quail. It is an antioxidant with anti-inflammatory properties and as such has potential as a therapeutic agent in atherosclerotic cardiovascular disease. Synthetic forms of astaxanthin have been manufactured. The safety, bioavailability and effects of astaxanthin on oxidative stress and inflammation that have relevance to the pathophysiology of atherosclerotic cardiovascular disease, have been assessed in a small number of clinical studies. No adverse events have been reported and there is evidence of a reduction in biomarkers of oxidative stress and inflammation with astaxanthin administration. Experimental studies in several species using an ischaemia-reperfusion myocardial model demonstrated that astaxanthin protects the myocardium when administered both orally or intravenously prior to the induction of the ischaemic event. At this stage we do not know whether astaxanthin is of benefit when administered after a cardiovascular event and no clinical cardiovascular studies in humans have been completed and/or reported. Cardiovascular clinical trials are warranted based on the physicochemical and antioxidant properties, the safety profile and preliminary experimental cardiovascular studies of astaxanthin.
引用
收藏
页码:447 / 465
页数:19
相关论文
共 50 条
  • [1] Astaxanthin in Cardiovascular Health and Disease
    Fassett, Robert G.
    Coombes, Jeff S.
    MOLECULES, 2012, 17 (02) : 2030 - 2048
  • [2] Astaxanthin in Liver Health and Disease: A Potential Therapeutic Agent
    Li, Jingjing
    Guo, Chuanyong
    Wu, Jianye
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2020, 14 : 2275 - 2285
  • [3] Astaxanthin as a Potential Neuroprotective Agent for Neurological Diseases
    Wu, Haijian
    Niu, Huanjiang
    Shao, Anwen
    Wu, Cheng
    Dixon, Brandon J.
    Zhang, Jianmin
    Yang, Shuxu
    Wang, Yirong
    MARINE DRUGS, 2015, 13 (09): : 5750 - 5766
  • [4] Therapeutic Potential of Astaxanthin in Diabetic Kidney Disease
    Naito, Yuji
    Uchiyama, Kazuhiko
    Handa, Osamu
    Aoi, Wataru
    CAROTENOIDS: BIOSYNTHETIC AND BIOFUNCTIONAL APPROACHES, 2021, 1261 : 239 - 248
  • [5] Therapeutic potential of quercetin as a cardiovascular agent
    Patel, Rahul V.
    Mistry, Bhupendra M.
    Shinde, Surendra K.
    Syed, Riyaz
    Singh, Vijay
    Shin, Han-Seung
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2018, 155 : 889 - 904
  • [6] Astaxanthin: A promising therapeutic agent for organ fibrosis
    Li, Ke
    Wang, Wenhong
    Xiao, Weihua
    PHARMACOLOGICAL RESEARCH, 2023, 188
  • [7] Therapeutic potential of astaxanthin and superoxide dismutase in Alzheimer's disease
    Balendra, Vyshnavy
    Singh, Sandeep Kumar
    OPEN BIOLOGY, 2021, 11 (06)
  • [8] Cardiovascular disease and the potential protective role of antioxidants
    Oguntibeju, O. O.
    Esterhuyse, A. J.
    Truter, E. J.
    AFRICAN JOURNAL OF BIOTECHNOLOGY, 2009, 8 (14): : 3107 - 3117
  • [9] Astaxanthin in cardiovascular health and disease: mechanisms of action, therapeutic merits, and knowledge gaps
    Visioli, Francesco
    Artaria, Christian
    FOOD & FUNCTION, 2017, 8 (01) : 39 - 63
  • [10] Therapeutic potential of ALKB homologs for cardiovascular disease
    Xiao, Ming-Zhu
    Liu, Jia-Ming
    Xian, Cui-Ling
    Chen, Keng-Yu
    Liu, Zhong-Qiu
    Cheng, Yuan-Yuan
    BIOMEDICINE & PHARMACOTHERAPY, 2020, 131